Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jan Krönke

Professor

Charité - Universitätsmedizin Berlin

Germany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (23)

Gerald Willimsky

Professor

Charité - Universitätsmedizin Berlin

GERMANY

View details

Michael Korenkov

Charité - Universitätsmedizin Berlin

GERMANY

View details

Arnd Kleyer

Head of Outpatient Sector

Charité - Universitätsmedizin Berlin

GERMANY

View details

Christian Furth

GERMANY

View details

Gerhard Krönke

GERMANY

View details

Markus M. Lerch

University Medicine Greifswald

GERMANY

View details

Ulrich Keller

Prof. Dr.

Charité - Universitätsmedizin Berlin

GERMANY

View details

Güliz Acker

Charité - Universitätsmedizin Berlin

GERMANY

View details

Christian Steinebach

Professor of Pharmaceutical/Medicinal Chemistry

University of Greifswald

GERMANY

View details

Markus Blaurock

University Medicine Greifswald

GERMANY

View details

K. Martin Kortüm

University Hospital Würzburg

GERMANY

View details

Christian Joachim Entenmann

Charité - Universitätsmedizin Berlin

GERMANY

View details

Christian Sebastian Michel

Attending physician, Head of Myeloma Service

University Medical Center of the Johannes Gutenberg University Mainz

GERMANY

View details

Katja C. Weisel

University Medical Center Hamburg-Eppendorf

GERMANY

View details

Olaf Heidenreich

Senior group leader

Princess Máxima Center for Pediatric Oncology

NETHERLANDS

View details

Ali Aghdassi

University Medicine Greifswald

GERMANY

View details

Thula Cannon Walter-Rittel

GERMANY

View details

Mats L. Wiese

Junior Professor

FH Münster

GERMANY

View details

Robert Biesen

Charité - Universitätsmedizin Berlin

GERMANY

View details

Carsten Müller-Tidow

Medical Director

University Hospital Heidelberg

GERMANY

View details

Marc S. Raab

University Hospital Heidelberg

GERMANY

View details

Anne Troldborg

Aarhus University

DENMARK

View details

Frank Buttgereit

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jan Krönke

Research Interests

Make your next move.

Explore related searches

Articles (20)

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

A Facile Protocol for C(sp2)-C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands.

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.

Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma.

Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy.

Malnutrition in gastrointestinal cancer manifests before systemic therapy and is associated with fatigue and reduced physical quality of life.

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series.

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Value of functional iron parameters in diagnostic re-assessment of MPN: refinement of iron-deficiency markers by zinc protoporphyrin (ZPP).

A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia

Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation

A phase I study of MAGE-A1-targeted T1367 T-cell receptorbased cell therapy in patients with advanced multiple myeloma.

Donor-Derived Clonal Haematopoiesis after Allogeneic Stem-Cell Transplantation: A Case Report.

Enhancing Solubility in VHL-Based PROTACs: Optimized USP7 Degraders for Improved Developability.

Functional and molecular analyses reveal impaired HSPCs in Multiple Myeloma patients post-induction.

Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study group.

Targetable BIRC5 dependency in therapy-resistant TP53 mutated acute myeloid leukemia.

Collaborators (23)

Gerald Willimsky

Michael Korenkov

Arnd Kleyer

Christian Furth

Gerhard Krönke

Markus M. Lerch

Ulrich Keller

Güliz Acker

Christian Steinebach

Markus Blaurock

K. Martin Kortüm

Christian Joachim Entenmann

Christian Sebastian Michel

Katja C. Weisel

Olaf Heidenreich

Ali Aghdassi

Thula Cannon Walter-Rittel

Mats L. Wiese

Robert Biesen

Carsten Müller-Tidow

Marc S. Raab

Anne Troldborg

Frank Buttgereit

Make your next move.